Bizarre Patents
A small umbrella which may be removably attached to a beverage container in order to shade the beverage container from the direct rays of the sun.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8173159 | Microcapsules A novel microcapsule comprising an encapsulated material which is enclosed within a solid permeable shell of a polymer resin having surface modifying compounds capable of reacting with isocyanate incorporated therein is disclosed. The process for producing such micr... | 05/08/2012 |
| 8105625 | Rapidly dissolving pharmaceutical compositions comprising pullulan The present invention provides an orally dissolving capsule comprising pullulan, a plasticizer and a dissolution enhancing agent. ... | 01/31/2012 |
| 8092829 | Use of R-arylpropionic acids for treating illnesses with a rheumatic nature The invention relates to the use of R-enantiomers of arylpropionic acids or the pharmacologically acceptable salts or derivatives thereof, in a pure or enriched form in contrast to the racemic compound, for the production of medicaments which inhibit the activation ... | 01/10/2012 |
| 8057819 | Stability additives for dry DHA dosage forms The use of additives to stabilize DHA when compressed into tablets, or filled as a powder into capsules, for oral administration. ... | 11/15/2011 |
| 8034377 | DHA esters and use thereof in treatment and prevention of cardiovascular disease The present invention relates to a docosahexaenoic acid ester with an alcohol chosen among the group-B vitamins or provitamins, advantageously comprised by: nicotinyl alcohol of the following formula (I), panthenol of the following formula (II), and inositol of the ... | 10/11/2011 |
| 8017148 | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant agent Disclosed in certain embodiments is an oral dosage form comprising: a therapeutically effective amount of an opioid analgesic; an opioid antagonist; and an irritant in an effective amount to impart an irritating sensation to an abuser upon ... | 09/13/2011 |
| 7988993 | Oral controlled release dosage form A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride. ... | 08/02/2011 |
| 7988994 | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fib... | 08/02/2011 |
| 7947305 | Fat-soluble drug composition The present invention aims at providing a fat-soluble drug composition having improved absorbability of the fat-soluble component in the living body and being stable as a formulation, specifically a fat-soluble drug composition for capsules. The present invention re... | 05/24/2011 |
| 7923026 | Embedded micellar nanoparticles The present invention relates to a thermostable solid composition containing nanosized micelles, the micelles containing a poorly soluble chemical substance, such as a biologically active substance, dissolved in an auxiliary material, and the micelles being embedded... | 04/12/2011 |
| 7887838 | Non-gelatin film and method and apparatus for producing same A film-forming composition comprising a hydrocolloid, a plasticizer, and water is described. A process and apparatus for producing a non-gelatin film comprising a hydrocolloid, a plasticizer, and water is also disclosed. The process includes combining at least one n... | 02/15/2011 |
| 7871643 | Pharmaceutical form having a two-layer separating layer A pharmaceutical form, contains an active compound-containing core, which is covered with a coating layer of a gastric juice-resistant, intestinal juice-soluble (meth)acrylate copolymer, a separating layer situated between said core and said coating layer, the separ... | 01/18/2011 |
| 7846475 | Soft capsules The present invention provides soft capsules comprising a capsule shell having a water activity lower than that of a capsule filling; and a production process of the soft capsules. The present invention makes it possible to prepare soft capsules without lowering the... | 12/07/2010 |
| 7815936 | Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions The use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions, the pharmaceutical compositions per se, as well as an adsorbate consisting of the granular material and at least one further substance selected from pharmac... | 10/19/2010 |
| 7767225 | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fib... | 08/03/2010 |
| RE41148 | Oral pulsed dose drug delivery system A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is ... | 02/23/2010 |
| 7635489 | Ingestion of hyaluronic acid for improved joint health Methods and compositions are described for relieving joint pain and discomfort in a warm-blooded vertebrate by delivering via oral ingestion a nutritional supplement comprising an effective amount of hyaluronic acid, or a salt or digest thereof, and a nutritionally ... | 12/22/2009 |
| 7476402 | Methods and compositions for deterring abuse of opioid containing dosage forms This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix. ... | 01/13/2009 |
| 7452551 | Targeted compositions for diagnostic and therapeutic use Novel targeted compositions which may be used for diagnostic and therapeutic use. The compositions may comprise lipid, protein or polymer gas-filled vesicles which further comprise novel compounds of the general formula L-P-T, wherein L comprises a hydrophobic compo... | 11/18/2008 |
| 7417022 | Compounds and compositions for delivering active agents Modified amino acid compounds useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well. ... | 08/26/2008 |
| 7358222 | Preventing airway mucus production by administration of EGF-R antagonists Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks th... | 04/15/2008 |
| 7351853 | Method of manufacturing a granular mineral composition A method for forming mineral granules can be accomplished with a granulation reaction of edible acids and mineral bases to form mineral salts. The reaction is carried out in a manner that produces granules without requiring a binder or requiring the use of extrusion... | 04/01/2008 |
| 7341742 | Simethicone containing tablet composition and method A process and pharmaceutical composition containing simethicone and magnesium carbonate allows a higher production rate of simethicone containing tablets and a more consistent end product tablet. The magnesium carbonate prevents sticking of simethicone to tablet com... | 03/11/2008 |
| 7332182 | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant Disclosed in certain embodiments is an oral dosage form comprising: a therapeutically effective amount of an opioid analgesic; an opioid antagonist; and an irritant in an effective amount to impart an irritating sensation to an abuser upon ... | 02/19/2008 |
| 7318920 | Low water activity nutritional product having beneficial microbial and high oil content The present invention relates to a composition for the oral administration of beneficial microorganisms in a discrete dosage form, comprising about 10% to about 50% by weight of a starch component, about 25% to about 50% by weight of a sugar component, about 0-20% o... | 01/15/2008 |
| 7314642 | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from and related plants Assay-guided affinity fractionation and reverse phase high pressure liquid chromatography (HPLC) methodology to isolate, test and characterize the most active water-soluble ingredients within Cat's Claw, or Uncaria tomentos. These components appear to account... | 01/01/2008 |
| 7303762 | Absorption enhancers The invention relates to the use of hydrophilic aromatic alcohols to enhance the uptake of molecules, including biologically active macromolecules, into the body across the intestinal wall from the lumen of the gut; to compositions for oral administration which cons... | 12/04/2007 |
| 7297346 | Pharmaceutical formulations of modafinil The present invention is related to compositions of modafinil, including compositions of modafinil and one or more diluents, disintegrants, binders and lubricants, and the processes for their preparation thereof. ... | 11/20/2007 |
| 7288271 | Chlorogenic acid and an analog thereof for immune system stimulation The present invention relates to a preparation for stimulating or enhancing an immune system comprising one or more agents that stimulate T-lymphocytes in vivo. Such a preparation can be sued in the prophylaxis and/or treatment of a medical condition. The invention ... | 10/30/2007 |
| 7282221 | Antiviral product, use and formulation thereof An antiviral product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antiviral product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosag... | 10/16/2007 |
| 7276252 | Method and form of a drug delivery device, such as encapsulating a toxic core within a non-toxic region in an oral dosage form A drug delivery device such as an oral dosage form (ODF) with a toxic or potent core encapsulated by a non-toxic region. The non-toxic region may be a region including multiple layers, coatings, shells, and combinations thereof, which provides protection to and isol... | 10/02/2007 |
| 7273623 | Process for preparing tannate tablet, capsule or other solid dosage forms An active pharmaceutical ingredient is combined with tannic acid to form a tannate salt complex of the active ingredient. The active ingredient tannate salt complex without isolation or purification is then blended with pharmaceutically acceptable excipients to form... | 09/25/2007 |
| 7273622 | Super absorption Coenzyme Q An improved soft gelatin formulation and process methodology that increases single Coenzyme Q10 molecules presented to the absorption channels of the small intestines by providing medium chain triglycerides, Vitamin E and natural beta carotene to Coenzyme... | 09/25/2007 |
| 7265257 | Absorbent articles comprising a bodily exudate modifying agent and a film-forming skin care formulation Absorbent articles having enhanced absorption of bodily exudates are disclosed. The absorbent articles comprise a bodily exudate modifying agent and a skin care formulation. The bodily exudate modifying agent is capable of reducing the viscosity of bodily exudates s... | 09/04/2007 |
| 7264824 | Oral dosage form Oral dosage form for food and food supplement as well as dietetics comprising polyunsaturated acids in a xylose-hardened gelatine capsule with a retarded release time. ... | 09/04/2007 |
| 7255877 | Fenofibrate microparticles Fenofibrate microparticles are prepared using a combination of surface modifiers with a phospholipid. Particle size growth and stability are controlled while significantly smaller sized fenofibrate particles are produced. ... | 08/14/2007 |
| 7255921 | Non-gelatinous capsule shell composition and a capsule formed from the same Non-gelatinous capsule film compositions containing as the base a starch hydrolyzate having an average DE of less than 10 and an average molecular weight of not more than 30,000. These non-gelatinous capsule film compositions have stable moisture absorbing/releasing... | 08/14/2007 |
| 7247318 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate r... | 07/24/2007 |
| 7220429 | Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing A formulation of Coenzyme Q10, beta-carotenes, Vitamin E, and medium chain triglycerides in rice bran oil and an optional thickener, such as bee's wax, is provided in a soft gel capsule so that a maximum of the Coenzyme Q10 is absorbed by the h... | 05/22/2007 |
| 7205279 | Pharmaceutical compositions This invention provides a microemulsion pre-concentrate comprising a difficultly soluble active agent and a carrier medium comprising 1) a hydrophilic phase which comprises dimethylisosorbide and/or a lower alkyl alkanoic ester, 2) a lipophilic phase, and 3) a surfa... | 04/17/2007 |
